Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases

Clin Invest Med. 2017 Feb 19;40(1):E34-E39. doi: 10.25011/cim.v40i1.28052.

Abstract

Purpose: The antimicrobial peptide cathelicidin LL-37 plays a role in the immune response in the course of lung infections; however, the exact role of LL-37 in defense mechanisms against bacteria within the respiratory tract is has not been precisely described. The aim of our study was to evaluate LL-37 concentrations in the serum of pulmonary tuberculosis (TB) patients, patients with pneumonia caused by Gram-positive and Gram-negative bacteria and to compare them with those of healthy subjects.

Methods: Thirty TB patients, 30 patients with pneumonia caused by Gram-positive bacteria, 30 patients with pneumonia caused by Gram-negative bacteria, and 30 healthy control subjects were enrolled in the study. Serum LL-37 concentration was measured using an enzyme-linked immunosorbent assay (ELISA).

Results: The mean (± SEM) LL-37 concentration in patients with TB (13.94±5.13 ng/mL) was significantly higher than that in patients with Gram-positive bacteria-induced pneumonia (7.87±4.58 ng/mL, P=0.00077), in patients with Gram-negative bacteria-induced pneumonia (10.27±3.60 ng/mL, P=0.00730), and in control healthy subjects (1.75±0.71 ng/mL, P=0.00004).

Conclusion: Our data suggest that cathelicidin LL-37 is an important element of host defense in the course of bacterial diseases within the respiratory tract, particularly when the infection is caused by an intracellular pathogen.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antimicrobial Cationic Peptides / blood*
  • Cathelicidins
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pneumonia, Bacterial / blood*
  • Tuberculosis, Pulmonary / blood*

Substances

  • Antimicrobial Cationic Peptides
  • Cathelicidins